MTOR and ovarian cancer: Furthermore, two EOC PDX models were used to confirm the activity of itraconazole in ovarian cancers and revealed that combined treatment of itraconazole and paclitaxel markedly attenuated cancer weight, decreased microvessel density of PDX tumor as well as suppressed hedgehog and mTOR pathways in comparison with the control, paclitaxel-alone, or itraconazole-alone groups, suggesting that itraconazole suppressed endothelial cells rather than cancer cells by targeting several signaling pathways including angiogenesis, hedgehog and mTOR pathways 93.